Nalaganje...
Dasatinib can enhance paclitaxel and gemcitabine inhibitory activity in human pancreatic cancer cells
SRC and its activated form, phospho-SRC (pSRC), are aberrantly activated in pancreatic cancer and SRC represents a potential target for pancreatic cancer therapy. In this paper, we examined the inhibitory effect of dasatinib, a potent SRC inhibitor in combination with paclitaxel or gemcitabine on hu...
Shranjeno v:
| izdano v: | Cancer Biol Ther |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Taylor & Francis
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6606004/ https://ncbi.nlm.nih.gov/pubmed/30866697 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2019.1579956 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|